NCT07089927 Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial
| NCT ID | NCT07089927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Malignant Solid Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2027-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-07-02 with a primary completion date of 2027-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests the feasibility, usability and acceptability of a virtual art therapy assisted re-integration (AVATARS) intervention to improve biopsychosocial outcomes, such as anxiety, depression, resilience, emotional regulation, stress, and cognition, among adolescent and young adult (AYA) cancer survivors. AYA cancer survivors (especially those treated at adult cancer centers) historically experience worse psychosocial outcomes and lack age appropriate psychosocial support compared to older adult cancer survivors. Creative art therapy accesses the limbic system to provide a corrective emotional experience in response to trauma and can help patients visually express depression, anxiety, and existential fears, process traumatic events, and regain agency and control. The AVATARS intervention may be a feasible, useable and acceptable way to improve biopsychosocial outcomes among AYA cancer survivors.
Eligibility Criteria
Inclusion Criteria: * If young adult- aged 18-25 years of age at the time of enrollment and able to provide informed consent, if adolescent- aged 10-17 years at the time of enrollment and able to provide * Mild or greater depression \[Patient Health Questionnaire (PHQ-A) score \> 5\] * Received a cancer diagnosis during the past year, or completed cancer treatment within the past five years (extended survivorship) * Have access to an electronic device which supports virtual videoconferencing (e.g., personal device or public library access) * Able to read and write in English Exclusion Criteria: * Visual or cognitive impairment which may impede completing the art project or the data collection measures * Endorsed suicidality (via PHQ-A or otherwise)
Contact & Investigator
C. Robert Bennett, PhD, RN
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07089927 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 25 Years, studying Malignant Solid Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07089927 currently recruiting?
Yes, NCT07089927 is actively recruiting participants. Contact the research team at Becker.regina@mayo.edu for enrollment information.
Where is the NCT07089927 trial being conducted?
This trial is being conducted at Scottsdale, United States, Rochester, United States.
Who is sponsoring the NCT07089927 clinical trial?
NCT07089927 is sponsored by Mayo Clinic. The principal investigator is C. Robert Bennett, PhD, RN at Mayo Clinic. The trial plans to enroll 30 participants.